GT19506

GT19506 is a proteolysis-targeting chimera (PROTAC) designed to target and degrade the c-Myc oncogenic transcription factor. Developed by Kintor Pharmaceutical in collaboration with Peking University, GT19506 is intended for the treatment of c-Myc-driven malignancies, including B-cell lymphomas and small cell lung cancer (SCLC). c-Myc is a well-known but historically "undruggable" target that drives tumor progression in a vast majority of cancers. GT19506 works by recruiting an E3 ubiquitin ligase to c-Myc, leading to its polyubiquitination and subsequent degradation by the proteasome. In preclinical studies, it has shown potent degradation of c-Myc in HL-60 cells and selective inhibition of proliferation in B-cell malignant cell lines and SCLC cell lines, while sparing normal hematopoietic progenitor cells.